SNBIF (SNBIF) Stock Price & Analysis
SNBIF (SNBIF) rose 0.00% to USD 16.45 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.
SNBIF last closed at USD 16.45; the session ranged USD 3.85–3.85 on volume of 1,000 shares. Market capitalization is $1.28B, with a 52-week range of USD 3.85–16.45 (PNK). Source: Nexqual, June 10, 2026 at 00:44 UTC.
Key Statistics (as of June 10, 2026 at 00:44 UTC)
| Price | USD 16.45 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 16.45 |
| Open | USD 3.85 |
| Day Range | USD 3.85 – 3.85 |
| 52-Week Range | USD 3.85 – 16.45 |
| Volume | 1,000 shares |
| Market Cap | $1.28B |
| Exchange | PNK |
Technical Analysis (SNBIF)
Nexqual's technical model rates SNBIF "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 16.45) |
| MACD | 0 (negative) |
Analyst Ratings (SNBIF)
Wall Street analysts rate SNBIF "None", per Nexqual as of June 10, 2026 at 00:44 UTC.
| Consensus Rating | None |
|---|
Earnings (SNBIF)
| Next Earnings Date | 2026-06-15 |
|---|
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financials & Fundamentals (SNBIF)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -50.00% |
| Debt / Equity | 9.1 |
| Current Ratio | 29.01 |
| Total Cash | $15.08B |
| Total Debt | $1.24B |
| Free Cash Flow | $-2.47B |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Financial Health Score (SNBIF)
Nexqual rates SNBIF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $15.1B cash vs $1.24B debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$3.76B |
| Efficiency | Critical — ROE -50%, ROA -24.9% |
Ownership (SNBIF)
| Insider Ownership | +24.92% |
|---|---|
| Institutional Ownership | +8.07% |
| Shares Outstanding | 78.04M |
| Float | 56.79M |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Leadership (SNBIF)
SNBIF is led by Keita Mori (age 58), Co-Founder, President, Executive Officer, CEO & Representative Director, per Nexqual as of June 10, 2026 at 00:44 UTC.
| Co-Founder, President, Executive Officer, CEO & Representative Director | Keita Mori (age 58) |
|---|---|
| Co-Founder & Executive Chairman | Toru Kawanishi (age 58) |
Major Backers & Investors (SNBIF)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.88% |
| State Street | 0.29% |
Source: Nexqual, June 10, 2026 at 00:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.4 | ▲ 0% |
| SOLTF | NXERA PHARMA CO LTD | USD 6.1 | ▼ 1.37% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| DMTRF | 3-D MATRIX LTD | USD 2.25 | ▲ 0% |
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.